Nanoemulsion loaded with lycobetaine–oleic acid ionic complex: physicochemical characteristics, in vitro, in vivo evaluation, and antitumor activity
Hui Zhao, Hua Lu, Tao Gong, Zhirong Zhang
Key Laboratory of Drug Targeting, Ministry of Education, Sichuan University, Chengdu, People's Republic of China
Background: Intravenous injection of lycobetaine was found to show significant cytotoxic activity against (inter alia) Lewis lung carcinoma, but its therapeutic use is largely limited due to an extremely short half-life in blood. This study aimed at developing a novel lipid nanocarrier-based formulation for lycobetaine delivery. The formulation is feasible for scale-up production, exhibiting good parenteral acceptability and improved circulation characteristics.
Methods: To enhance its lipophilicity, oleic acid was selected to form ionic complexes with lycobetaine (LBT). The nanoemulsion loaded with LBT–oleic acid complex (LBT–OA–nanoemulsion) and PEGylated LBT–OA–nanoemulsion (NE) (LBT–OA–PEG–NE) were prepared by a simple high-pressure homogenization method.
Results: A high-encapsulation efficiency of around 97.32% ± 2.09% was obtained for LBT–OA–PEG–NE under optimized conditions. Furthermore, the in vivo pharmacokinetics and biodistribution of LBT–OA–NE, LBT–OA–PEG–NE, and free LBT were studied in rats. Free LBT and LBT–OA–PEG–NE displayed AUC0–10h (area under the concentration-time curve from 0 to 10 hours) of 112.99 mg/L*minute and 3452.09 mg/L*minute via intravenous administration (P < 0.005), respectively. Moreover, LBT–OA–PEG–NE showed significantly lower LBT concentration in the heart, liver, and kidney, while achieving higher concentration of LBT in the lung when compared to free LBT at the same time (P < 0.005). The LBT–OA–PEG–NE exhibited higher growth inhibitory effect and longer survival time than free LBT in both heterotopic and lung metastatic tumor models.
Conclusion: These results demonstrated that LBT–OA–PEG–NE is an attractive parenteral formulation for cancer therapy.
Keywords: lycobetaine, oleic acid, polyethylene glycol, nanoemulsion, in vivo studies, antitumor activity
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Readers of this article also read:
Roy K, Kanwar RK, Kanwar JR
Published Date: 26 August 2015
Wu P, Li S, Zhang H
Published Date: 5 December 2014
Erturk A, Adnan Akdogan R, Parlak E, Cure E, Cumhur Cure M, Ozturk C
Published Date: 29 May 2014
Relapsed Hodgkin lymphoma in adolescents: focus on current high-dose chemotherapy and autologous stem cell transplant
Guilcher GM, Stewart DA
Published Date: 8 May 2014
Soosay Raj TA, Smith AM, Moore AS
Published Date: 6 November 2013
Photodynamic therapy of a 2-methoxyestradiol tumor-targeting drug delivery system mediated by Asn-Gly-Arg in breast cancer
Shi J, Wang Z, Wang L, Wang H, Li L, Yu X, Zhang J, Ma R, Zhang Z
Published Date: 19 April 2013
Algahim MF, Almassi GH
Published Date: 11 February 2013
Saifullah B, Hussein MZ, Hussein Al Ali SH
Published Date: 12 October 2012
Published Date: 8 December 2011
Published Date: 17 September 2010